"The committee has come to a clear scientific conclusion: This is a safe and effective vaccine. Its benefits in protecting people from #COVID19 with the associated risks of death and hospitalization outweigh the possible risks”, says Emer Cooke at @EMA_News press conference.
@EMA_News "The committee also concluded that the vaccine is not associated with an increase in the overall risk of thrombo embolic events or blood clots”, says Cooke.
@EMA_News "During the investigation and review we began to see a small number of cases of rare and unusual but very serious clotting disorders, and this then triggered a more focused review based on the evidence available”, says Cooke.
@EMA_News “After days of in-depth analysis of lab results, clinical reports, autopsy reports and other information from the clinical trials, we still cannot rule out definitively a link between these cases and the vaccine”, says Cooke.
@EMA_News “What the committee has therefore recommended is to raise awareness of these possible risks making sure that they're included in the product information, drawing attention to these possible rare conditions”, says Cooke.
@EMA_News "We're also launching additional investigations to understand more about these rare cases, and we're conducting targeted observational studies”, says Cooke.
@EMA_News "I want to reiterate that our scientific position is that this vaccine is a safe, an effective option to protect citizens against #COVID19”, says Cooke.
@EMA_News "We're very much aware that some member states have paused vaccinations, waiting for EMA's outcome of a review”, says Cooke. “But given that 1000s of people in the EU die every day. … it really was crucial for EMA to review rapidly and thoroughly all the available evidence."
@EMA_News “This vaccine is safe and effective in preventing #COVID19 and its benefits continue to be far greater than its risks. PRAC has found no evidence of a quality or a batch issue”, says Sabine Straus, chair of EMA's safety committee (PRAC).
@EMA_News “PRAC has concluded that there was no increase in the overall risk of blood clots”, says Straus. “Moreover, because the vaccine is effective in preventing #COVID19 disease, which in itself, of course, is a cause of blood clots, it likely reduces the risk of thrombotic events."
@EMA_News “However, there are also still some uncertainties”, says Straus. "We have seen some very rare case reports, describing specific unusual events of a combination of thrombosis and thrombocytopenia and bleeding.” Mentions disseminated intravascular coagulation (DIC) and CVTs.
@EMA_News “The evidence we have is, at the moment, not sufficient to conclude with certainty whether these adverse events are indeed caused by the vaccine or not”, says Straus . "So PRAC will continue to gather more information on these conditions, including additional studies…"
@EMA_News “PRAC also concluded that it's very important that these events are rare”, says Straus. "As of last night, seven cases of this disseminated intravascular coagulation and 18 cases of cerebral venous sinus thrombosis were reported out of almost 20 million vaccinated people."
@EMA_News “PRAC has recommended to add a warning to the SMPC and the patient leaflets and the description of these cases, so that this information should be provided to healthcare professionals and to the public”, says Straus.
@EMA_News "EMA and national health authorities will ensure that health care professionals and the general public are made aware of this information and made aware of the signs and symptoms of concern so that timely action can be taken to mitigate these risks”, says Straus.
@EMA_News EMA also just sent out a press release with this information for patients:
@EMA_News So seek prompt medical assistance if you get any of these after vaccination:
- breathlessness
- pain in the chest or stomach
- swelling or coldness in an arm or leg
- severe or worsening headache or blurred vision after vaccination
- persistent bleeding
- multiple small bruises
• • •
Missing some Tweet in this thread? You can try to
force a refresh
EMA press conference on AstraZeneca safety signal is scheduled for 16.00 for now.
Just to give you an idea of what I will be looking out for, here are a few questions I would love to have answers to (and I don’t expect we can answer all of them already):
- Is there a significantly elevated number of people with the described clinical picture (widespread blood clotting, low platelet count, cerebral venous thrombosis) amongst vaccinees?
- Are there other things that unite them?
- Is there a common diagnosis? HUS, DIC, something?
- Is the age and gender distribution amongst cases unusual or in line with who was given the vaccine?
- Are most or all of the cases linked to a specific manufacturing plant?
- Any data on what treatments may have worked or not worked in these patients?
A lot to say about AZ vaccine pause in Europe, but I will try to stick to a two key questions in this thread (more later): 1. What are the symptoms that have led to the pause? 2. Is there a plausible mechanism for the vaccine causing them?
1. There has been a lot of general talk about blood clots and deep vein thrombosis, but the picture described to @GretchenVogel1 and me by doctors and regulatory agencies is a much more complicated one and based on at least 13 previously healthy individuals from 5 countries.
@GretchenVogel1 Main characteristics seem to be:
- widespread blood clots
- few platelets (thrombocytopenia)
- internal bleeding
- cerebral venous thrombosis
As @steinarma told us: “It’s a very special picture”.
Getting a TON of questions about AZ vaccine safety, so a few points as you watch news unfold the next days:
- There are no clear answers yet. Getting them will take time.
- There is a lot of bad info and speculation out there. Think long and hard about what sources you trust.
- Information flow takes time. So some dissonance now between different assessments may disappear when all have the same data on which to base their assessments. For now data from national authorities like that provided by PEI is most likely to be up-to-date.
- People are making extremely difficult decisions with a lot of uncertainty between two risky/bad outcomes.
If you think it is obvious what has to be done, at least consider that maybe you do not have all the information. Or maybe you have not thought all that hard about it.
“I'm not here to give you the outcome of any scientific review”, says EMA director Emer Cooke at start of press conference on AstraZeneca vaccine safety. "I'm here to explain the steps in the process, what we're doing, and when you can expect us to come to a conclusion."
“This is not unexpected”, says Emer Cooke. “When you vaccinate millions of people, it's inevitable that you have rare or serious incidences of illnesses that occur after vaccination”. Role of EMA is to evaluate whether there is a causal effect or it is coincidence, she says.
Experts will meet Thursday "to come to a conclusion on the full information that has been gathered and to advise us as to whether there are any further actions that need to be taken”, says Cooke. “We will inform the public of the outcome immediately after this meeting."
“More countries have suspended the use of AstraZeneca vaccines as a precautionary measure, after reports of blood clots in people who had received the vaccine from two batches produced in Europe”, says @DrTedros at @WHO presser on #covid19.
@DrTedros@WHO "This does not necessarily mean these events are linked to vaccination”, says @drtedros. "WHO’s Advisory Committee on Vaccine Safety has been reviewing the available data, is in close contact with the @EMA_News and will meet tomorrow."
@DrTedros@WHO@EMA_News “But the greatest threat that most countries face now is lack of access to #COVID19 vaccines”, says @drtedros. "Almost every day, I receive calls from senior political leaders around the world, asking when their country will receive their vaccines through COVAX."
Lab-confirmed infections this time last year: 119,820
This year: 449
You read that right
@rki_de There is also a sentinel program in which doctors send in samples from patients with respiratory disease symptoms to the national reference laboratory.
Number of samples with influenza viruses this time last year: >600
This year: 0
@rki_de The situation in Germany mirrors that in countries across the world. Here is the excellent @HelenBranswell with the view from the US: